{Reference Type}: Case Reports
{Title}: Type I acquired cutis laxa: Report of a unique progressive case and short review.
{Author}: Peralta-Amaro AL;Quintal-Ramírez MJ;Esteban-Prado A;Chávez-Sánchez IN;Vera-Lastra OL;López-Velasco A;Acosta-Jiménez E;Cano-Viveros MI;
{Journal}: Am J Med Sci
{Volume}: 367
{Issue}: 4
{Year}: 2024 Apr 24
{Factor}: 3.462
{DOI}: 10.1016/j.amjms.2024.01.015
{Abstract}: Cutis laxa is a rare connective tissue disorder, characterized by a reduced number and abnormal properties of elastic fibers throughout the dermis, creating a clinical appearance of premature aging. It can be subdivided into inherited and acquired, the latter rarer than the former, and skin involvement may be localized or generalized. The etiology of acquired cutis laxa (ACL) remains unknown and there is no definitive treatment. We present the case of a 30-year-old man diagnosed with type I ACL with progressive systemic involvement at the renal, pulmonary, and digestive levels. Histological analysis of the skin revealed reduction and fragmentation of elastic fibers. Immunosuppressive treatment was started with prednisone, cyclophosphamide, and rituximab, with which a complete response to proteinuria was achieved and the progression of lung damage was limited. Autoimmune, infectious, and neoplastic diseases were ruled out.